Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 4/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TTR | P02766 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 3/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA4 | P22748 | 2/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.31 |
| ▸ | MGMT | P16455 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14922170 | 1.00 | CRBN (0.38) | CRBNMEN1KMT2ACA2SMN1; SMN2 | |
| SCHEMBL30242774 | 1.00 | CRBN (0.38) | CRBNMEN1KMT2ACA2SMN1; SMN2 | |
| SCHEMBL18886281 | 0.88 | CRBN (0.41) | CRBNMEN1KMT2ACA2SMN1; SMN2 | |
| SCHEMBL17282361 | 0.88 | CRBN (0.41) | CRBNMEN1KMT2ACA2SMN1; SMN2 | |
| SCHEMBL19164024 | 0.88 | CRBN (0.38) | CRBNMEN1KMT2ACA2SMN1; SMN2 | |
| SCHEMBL14922169 | 0.87 | CRBN (0.38) | CRBNMEN1KMT2ACA2SMN1; SMN2 | |
| SCHEMBL31174135 | 0.87 | CRBN (0.38) | CRBNMEN1KMT2ACA2SMN1; SMN2 | |
| SCHEMBL24795789 | 0.87 | CRBN (0.38) | CRBNMEN1KMT2ACA2SMN1; SMN2 | |
| SCHEMBL18886307 | 0.87 | CRBN (0.38) | CRBNMEN1KMT2ACA2SMN1; SMN2 | |
| SCHEMBL13695971 | 0.87 | CRBN (0.38) | CRBNMEN1KMT2ACA2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240000964-A1 | COMPOUND OR SALT THEREOF, AND ANTIBODY OBTAINED BY USING THE SAME | AJINOMOTO CO., INC. (JP) | 2024-01-04 | — | — | US | disclosed |
| EP-4279502-A1 | COMPOUND OR SALT THEREOF, AND ANTIBODY OBTAINED THEREFROM | AJINOMOTO CO., INC. (JP) | 2023-11-22 | — | — | EP | disclosed |
| CN-116761819-A | Compounds or salts thereof, and antibodies derived therefrom | 味之素株式会社 | 2023-09-15 | — | — | CN | disclosed |
| US-20230248837-A1 | Technology for Modulating Targeting Chimeras Induced by Cell-Penetrating Peptide and Application Thereof | LIU, MIAO (CN) | 2023-08-10 | — | — | US | disclosed |
| WO-2022154127-A1 | COMPOUND OR SALT THEREOF, AND ANTIBODY OBTAINED THEREFROM | 味の素株式会社 | 2022-07-21 | — | — | WO | disclosed |
| US-20210139549-A1 | COMPOUND HAVING AFFINITY SUBSTANCE TO ANTIBODY, CLEAVABLE PORTION, AND REACTIVE GROUP, OR SALT THEREOF | AJINOMOTO CO., INC. (JP) | 2021-05-13 | — | — | US | disclosed |
| EP-3808760-A1 | COMPOUND COMPRISING SUBSTANCE HAVING AFFINITY FOR ANTIBODY, CLEAVAGE SITE AND REACTIVE GROUP, OR SALT THEREOF | AJINOMOTO CO., INC. (JP) | 2021-04-21 | — | — | EP | disclosed |
| CN-112262152-A | Compound having affinity substance, cleavable moiety and reactive group for antibody, or salt thereof | 味之素株式会社 | 2021-01-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240000964-A1 | COMPOUND OR SALT THEREOF, AND ANTIBODY OBTAINED BY USING THE SAME | SSB, CTH, SCLY | CRBN 340/4885MEN1 2419/4885KMT2A 991/4885 |
| US-20210139549-A1 | COMPOUND HAVING AFFINITY SUBSTANCE TO ANTIBODY, CLEAVABLE PORTION, AND REACTIVE GROUP, OR SALT THEREOF | FCGR3B, FCGR2A, FCGR1A | CRBN 676/4885MEN1 1262/4885KMT2A 922/4885 |
| US-20230248837-A1 | Technology for Modulating Targeting Chimeras Induced by Cell-Penetrating Peptide and Application Thereof | VIP, GHITM, MYCBP | CRBN 226/4885MEN1 1339/4885KMT2A 3720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.